2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

RD cell

" in MedChemExpress (MCE) Product Catalog:

20

Inhibitors & Agonists

1

Inhibitory Antibodies

6

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0043
    Ginsenoside Rd
    1 Publications Verification

    Gypenoside VIII

    		 NF-κB COX Calcium Channel Cytochrome P450 Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology Cancer
    Ginsenoside Rd inhibits TNFα-induced NF-κB transcriptional activity with an IC50 of 12.05±0.82 μM in HepG2 cells. Ginsenoside Rd inhibits expression of COX-2 and iNOS mRNA. Ginsenoside Rd also inhibits Ca 2+ influx. Ginsenoside Rd inhibits CYP2D6, CYP1A2, CYP3A4, and CYP2C9, with IC50s of 58.0±4.5 μM, 78.4±5.3 μM, 81.7±2.6 μM, and 85.1±9.1 μM, respectively.
    Ginsenoside Rd
  • HY-14925
    Lapaquistat
    2 Publications Verification

    T-91485

    		 Endogenous Metabolite Drug Metabolite Metabolic Disease
    Lapaquistat (T-91485), a cholesterol biosynthesis inhibitor, is the active metabolite of Lapaquistat acetate (HY-16274). Lapaquistat can decrease statin-induced myotoxicity in lipid-lowering therapy .
    Lapaquistat
  • HY-W019806
    Lacto-N-fucopentaose I

    LNFP I

    		 Endogenous Metabolite CDK Reactive Oxygen Species (ROS) Apoptosis Enterovirus Bacterial Infection Inflammation/Immunology
    Lacto-N-fucopentaose I (LNFPI) is a human milk oligosaccharide (HMO), possessing antiviral and antibacterial activity. Lacto-N-fucopentaose I can reduce capsid protein VP1 to block virus adsorption, promote CDK2 and reduce cyclin E to recover cell cycle S phase block. Lacto-N-fucopentaose I inhibits ROS production and apoptosis in virus-infected cells. Lacto-N-fucopentaose I can also regulate intestinal microbiota to affect immune system development .
    Lacto-N-fucopentaose I
  • HY-N1966
    (E)-Osmundacetone
    2 Publications Verification

    		 p38 MAPK PPAR Cancer
    (E)-Osmundacetone is an inhibitor of the MAPK pathway. (E)-Osmundacetone inhibits the activation of the MAPK signaling pathway and restores the expression of PPARα/ACOX1. (E)-Osmundacetone abrogates abnormal cell proliferation, migration and liver metastasis induced by PTPRO silencing in colorectal cancer cells. (E)-Osmundacetone blocks OA-RD17-mediated activation of the MAPK signaling pathway, thereby reducing macrophage proliferation and migration. (E)-Osmundacetone is applicable to relevant research on colorectal cancer .
    (E)-Osmundacetone
  • HY-136913
    (Rac)-Rhododendrol

    (Rac)-Betuligenol

    		 Endogenous Metabolite Inflammation/Immunology
    (Rac)-Rhododendrol ((Rac)-Betuligenol) is an aromatic compound with pro-oxidant activity. (Rac)-Rhododendrol may be useful in the suppression of liver diseases. (Rac)-Rhododendrol can be toxic to melanocytes, leading to cell death. The metabolite of (Rac)-Rhododendrol, RD-quinone, is cytotoxic and causes enzyme inactivation and endoplasmic reticulum stress by binding to thiol proteins. (Rac)-Rhododendrol-derived melanin exhibits potent pro-oxidant activity and may cause oxidative stress .
    (Rac)-Rhododendrol
  • HY-W016407
    Methyl 3,4-dihydroxyphenylacetate

    		Enterovirus Infection
    Methyl 3,4-dihydroxyphenylacetate is a potent enterovirus 71 (EV71) infection inhibitor. Methyl 3,4-dihydroxyphenylacetate inhibits EV71 replication in rhabdomyosarcoma (RD) cells .
    Methyl 3,4-dihydroxyphenylacetate
  • HY-161687
    Cisplatin/Dasatinib prodrug-1

    		Src Cancer
    Cisplatin/Dasatinib prodrug-1 (Compound 3) is a prodrug of Cisplatin (HY-17394) and Dasatinib (HY-10181). Cisplatin/Dasatinib prodrug-1 exhibits antiproliferative activity against A2780, MDA-MB-231, MCF7, HCT116, RD, Thp1 and HL60 cancer cells with IC50s of 0.1, 0.1, 0.36, 2.0, 0.4, 0.3 and 0.25 μM, respectively .
    Cisplatin/Dasatinib prodrug-1
  • HY-178919
    N-19004

    		Formyl Peptide Receptor (FPR) Apoptosis Bacterial Inflammation/Immunology
    N-19004 is a FPR1 antagonist. N-19004 shows broad-spectrum antibacterial effects against a variety of pathogens. N-19004 exhibits significant retinal protective effects in the rd10 mouse model of retinitis pigmentosa (RP). N-19004 can attenuate retinal dysfunction, mitigate rod and cone degeneration, and reduce immune cell activation, gliosis, inflammation, oxidative stress, and apoptosis. N-19004 can reduce the size of laser-induced choroidal lesions and promote edema absorption through dual anti-inflammatory and anti-angiogenic effects. N-19004 can be used for the research of retinal degenerative diseases such as retinitis pigmentosa .
    N-19004
  • HY-175671
    LSD1/HDAC-IN-3

    		HDAC Histone Demethylase Neurological Disease
    LSD1/HDAC-IN-3 is a inhibitor targeting class I HDAC and LSD1 enzymes. LSD1/HDAC-IN-3 inhibits HDAC1, HDAC2, HDAC3, and LSD1 with IC50 values of 1702 nM, 842 nM, 358 nM, and 1074 nM, respectively. LSD1/HDAC-IN-3 exhibits antioxidant effects in H2O2-stressed ARPE-19 and 661W retinal cells, increasing levels of acetylated and methylated histone H3. LSD1/HDAC-IN-3 enhances photoreceptor survival in the rd10 mouse model of retinitis pigmentosa. LSD1/HDAC-IN-3 can be used for the study of inherited retinal diseases such as retinitis pigmentosa (RP) .
    LSD1/HDAC-IN-3
  • HY-162715
    EV-A71-IN-2

    		Enterovirus Infection
    EV-A71-IN-2 (compound 6c) is a anti-EV-A71 agent with the EC50 values of 0.29 μM and 1.66 μM aganist of EV-A71-MRC-5 cells and EV-A71-RD cells, respectively. EV-A71-IN-2 can be used for study of enterovirus infection .
    EV-A71-IN-2
  • HY-N0043R
    Ginsenoside Rd (Standard)

    Gypenoside VIII (StandaRD)

    		 Reference Standards NF-κB COX Calcium Channel Cytochrome P450 Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology Cancer
    Ginsenoside Rd (Standard) is the analytical standard of Ginsenoside Rd. This product is intended for research and analytical applications. Ginsenoside Rd inhibits TNFα-induced NF-κB transcriptional activity with an IC50 of 12.05±0.82 μM in HepG2 cells. Ginsenoside Rd inhibits expression of COX-2 and iNOS mRNA. Ginsenoside Rd also inhibits Ca2+ influx. Ginsenoside Rd inhibits CYP2D6, CYP1A2, CYP3A4, and CYP2C9, with IC50s of 58.0±4.5 μM, 78.4±5.3 μM, 81.7±2.6 μM, and 85.1±9.1 μM, respectively.
    Ginsenoside Rd (Standard)
  • HY-174402
    PLpro-IN-9

    		SARS-CoV Infection
    PLpro-IN-9 (Compound 14e) is a SARS-CoV-2 PLpro inhibitor with an IC50 of 12.0 μM and a KD of 1.86 μM. PLpro-IN-9 has low cytotoxicity but poor metabolic stability. PLpro-IN-9 can be used in the research of SARS-CoV-2 .
    PLpro-IN-9
  • HY-175740
    Antiviral agent 71

    		Enterovirus Infection
    Antiviral agent 71 (Compound 26) is an antiviral agent. Antiviral agent 71 has a broad-spectrum enterovirus antiviral activity, such as EV-D68, Echo-11 and HRV-14 with EC50s of 0.017-4.1 μM. EV-D68-IN-1 can be used for non-polio enteroviruses (NPEV) infections research .
    Antiviral agent 71
  • HY-N1966R
    (E)-Osmundacetone (Standard)

    		Reference Standards p38 MAPK PPAR Cancer
    (E)-Osmundacetone (Standard) is the analytical standard of (E)-Osmundacetone (HY-N1966). This product is intended for research and analytical applications. (E)-Osmundacetone is an inhibitor of the MAPK pathway. (E)-Osmundacetone inhibits the activation of the MAPK signaling pathway and restores the expression of PPARα/ACOX1. (E)-Osmundacetone abrogates abnormal cell proliferation, migration and liver metastasis induced by PTPRO silencing in colorectal cancer cells. (E)-Osmundacetone blocks OA-RD17-mediated activation of the MAPK signaling pathway, thereby reducing macrophage proliferation and migration. (E)-Osmundacetone is applicable to relevant research on colorectal cancer .
    (E)-Osmundacetone (Standard)
  • HY-P991898
    IASO-782

    RD126

    		 CD19 Inflammation/Immunology
    IASO-782 (RD126) is a fully human monoclonal antibody targeting human CD19. The Fc segment of IASO-782 is mutated to enhance antibody-dependent cell-mediated cytotoxicity (ADCC) while maintaining the integrity of other Fc segment functions, such as ADCP. IASO-782 effectively eliminates CD19+ B cells, plasmablasts, and some plasma cells, thereby reducing or completely eliminating autoreactive antibodies produced by these cells. IASO-782 can be used for the study of immune thrombocytopenic purpura (ITP), warm autoimmune hemolytic anemia (wAIHA) and systemic lupus erythematosus (SLE).
    IASO-782
  • HY-182971
    PROTAC EV-A71 Degrader-1

    		PROTACs Enterovirus Infection
    PROTAC EV-A71 Degrader-1 is a PROTAC degrader targeting EV-A71 3D polymerase, with broad-spectrum activity against a variety of enteroviruses. PROTAC EV-A71 Degrader-1 induces the degradation of EV-A71 3D polymerase through the ubiquitin-proteasome and autophagy-lysosome pathways, and blocks viral replication. PROTAC EV-A71 Degrader-1 protects infected mice from death, alleviates tissue damage, and exhibits safety profiles. PROTAC EV-A71 Degrader-1 can be used in the research of enterovirus infections. (Pink: EV-A71 ligand (HY-19339); Blue: E3 ligase ligand (HY-W012479); Black: linker (HY-W105744)) .
    PROTAC EV-A71 Degrader-1
  • HY-182403
    GR-891

    		Apoptosis Others Cancer
    GR-891 is an acyclic nucleoside 5-Fluorouracil (HY-90006) derivative. GR-891 exerts antiproliferative activity in human cancer cells and inhibits proliferation of human rhabdomyosarcoma cells. GR-891 induces terminal myogenic differentiation in human rhabdomyosarcoma cells, including modulation of desmin and vimentin expression. GR-891 is phosphorylated by kinases, incorporated into RNA, and releases acrolein. GR-891 can be used for the research of cancer and rhabdomyosarcoma .
    GR-891
  • HY-183011
    CRBN ligand-901

    		Ligands for E3 Ligase Others
    CRBN ligand-901 (5d in Scheme 2) is a ligand for Cereblon (CRBN). CRBN ligand-901 can be linked to target protein ligands (e.g., VP1 ligand-1) via a linker to form PROTAC molecules (e.g., Jun15702 (HY-182924)) .
    CRBN ligand-901
  • HY-181680
    ATPase-IN-8

    		Enterovirus Infection
    ATPase-IN-8 is an anti-enteroviral agent that inhibits the viral non-structural protein 2C, with an IC50 of 1.4 μM against CV-B3 2C ATPase. ATPase-IN-8 exhibits significant anti-enteroviral activity and acts as a potent, selective inhibitor of CV-B3 and EV-D68. ATPase-IN-8 can be used for research on enteroviral infections .
    ATPase-IN-8
  • HY-182924
    Jun15702

    		PROTACs Enterovirus Infection
    Jun15702 is a PROTAC degrader targeting the capsid protein VP1 of enterovirus D68. Jun15702 recruits the Cereblon (CRBN) E3 ligase and activates the ubiquitin-proteasome pathway. Jun15702 inhibits viral entry and exerts inhibitory effects during the early, middle and late stages of viral replication. Jun15702 exhibits antiviral activity against multiple wild-type enterovirus D68 strains, and also shows submicromolar antiviral activity against the Pleconaril (HY-19952)-resistant enterovirus D68 variant rMO-VP1 F159V. Jun15702 can be used in studies related to enterovirus D68 (EV-D68) infection .
    Jun15702

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: